ProAxsis Signs Global In-Licensing Agreement with AstraZeneca for Covid-19 Serology Test
June 07, 2021 at 02:00 am EDT
NetScientific plc announced that its wholly owned subsidiary ProAxsis Limited has entered into an exclusive licensing agreement with the global biopharmaceutical company AstraZeneca. ProAxsis will take responsibility for completing the validation and global commercialisation of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA (enzyme-linked immunosorbent assay) developed by an internal research team at AstraZeneca. In return for providing access to the required intellectual property and technical know-how, AstraZeneca will receive a royalty fee on future Global net sales of the assay.